I'm a title. Click here to edit me.
Targeted protein degradation
is our mission
Your partner for ‘Next Generation Targeted Protein Degradation Drug Discovery’
ApoRx is a drug discovery company focusing on the discovery, design, characterization, and development of small proteolysis targeting molecules (PTMs) against well-validated disease-causing proteins in cancer and other indications.
The core of our technology is the 'Aperion library' - a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular Ubiquitin-Proteasome machinery to degrade and destroy unwanted proteins by Targeted Protein Degradation.
Ness Tziona, IL